BPC-157 and Retatrutide Together: Risks, Evidence, and UK Guidance

BPC-157 and retatrutide together is a combination increasingly discussed in biohacking and fitness communities, yet it sits entirely outside the bounds of evidence-based medicine. BPC-157 is an unregulated synthetic peptide with no approved clinical use in the UK, while retatrutide is an investigational triple incretin receptor agonist still undergoing clinical trials. Neither holds a UK marketing authorisation from the MHRA. This article examines what each substance is, why combining them carries significant and unpredictable risks, what UK regulatory guidance says, and why speaking to a qualified healthcare professional is essential before considering either compound.

What Are BPC-157 and Retatrutide?

BPC-157 is an unregulated synthetic peptide studied only in animals, while retatrutide is an investigational triple incretin receptor agonist in clinical trials; neither holds a UK marketing authorisation.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. It has been investigated primarily in preclinical (animal) studies for its purported regenerative, anti-inflammatory, and cytoprotective properties. Proponents suggest it may support tendon and ligament healing, reduce gastrointestinal inflammation, and promote tissue repair. These claims are based almost entirely on rodent models; robust human clinical data do not exist. BPC-157 has not been approved as a medicine by any major regulatory authority, including the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK or the European Medicines Agency (EMA).^[1][2]

Retatrutide, by contrast, is an investigational pharmaceutical compound currently undergoing clinical trials. It is a triple agonist targeting the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. This triple-receptor mechanism distinguishes it from approved agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GLP-1/GIP agonist). Phase 2 clinical trial data published in the New England Journal of Medicine (2023) demonstrated significant reductions in body weight and improvements in metabolic markers, making retatrutide a subject of considerable scientific interest for the management of obesity and type 2 diabetes.^[3][4]

It is important to note that retatrutide is not currently approved for clinical use in the UK. It remains an experimental compound, accessible only within the context of regulated clinical trials. Neither substance holds a UK marketing authorisation, and both fall outside standard NHS prescribing pathways. Understanding this regulatory context is essential before considering either compound, let alone using them in combination.

Is It Safe to Use BPC-157 and Retatrutide Together?

There is no clinical evidence, human trial data, or regulatory guidance supporting the combined use of BPC-157 and retatrutide, making it impossible to establish safety for this combination.

There is currently no clinical evidence, published research, or regulatory guidance addressing the combined use of BPC-157 and retatrutide. No human trials have examined this combination, and no safety data exist to support or refute its use. Any claims circulating online or within fitness and biohacking communities about the benefits or safety of using these two substances together are not supported by peer-reviewed evidence.

Retatrutide, as a triple incretin receptor agonist, carries a known adverse effect profile based on its Phase 2 clinical trial data. Commonly reported side effects include:

• Nausea, vomiting, and diarrhoea — typical of GLP-1 receptor agonism

• Reduced appetite and early satiety

• Increased heart rate, as observed with GLP-1 receptor agonists as a class

• Risk of hypoglycaemia, primarily when used alongside insulin or sulfonylureas rather than as monotherapy

• Delayed gastric emptying, which may affect the absorption of orally administered medicines taken concurrently

• Risk of gallbladder disease, including cholelithiasis, a recognised class effect of GLP-1 receptor agonists^[9][10]

• Gastrointestinal discomfort, which may be dose-dependent

BPC-157, while generally described as well-tolerated in animal studies, lacks robust human safety data. Its purity, dosing, and formulation when sourced outside clinical settings are entirely unverified. Combining an unregulated peptide with an experimental pharmaceutical compound introduces unpredictable pharmacodynamic and pharmacokinetic variables that cannot be assessed without formal study.

Given that both substances affect metabolic, gastrointestinal, and potentially systemic pathways, the theoretical risk of additive or synergistic adverse effects — particularly on gastrointestinal function, blood pressure, and appetite regulation — cannot be dismissed. There is no basis on which a clinician could currently endorse this combination as safe, and individuals considering it should be aware that they would be doing so entirely without medical evidence or regulatory oversight.

If you experience any suspected side effects from either substance, you can report these to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Current Evidence and Regulatory Status in the UK

Neither BPC-157 nor retatrutide holds MHRA approval; BPC-157 is often sold illegally as a research chemical, and retatrutide remains accessible only within regulated clinical trials.

In the UK, medicines intended for use in humans must ordinarily hold a marketing authorisation granted by the MHRA, or be used within the framework of a regulated clinical trial under a Clinical Trial Authorisation (CTA). A further lawful route exists — the supply of unlicensed medicines as 'specials' — but this applies only in specific, tightly regulated circumstances where a licensed alternative is unavailable and a prescriber takes individual clinical responsibility. Neither BPC-157 nor retatrutide is appropriate for use under any of these frameworks in routine practice. Retatrutide is being studied in Phase 2 and Phase 3 clinical trials internationally but has not received approval from the MHRA, the EMA, or the US Food and Drug Administration (FDA) as of the time of writing.

BPC-157 occupies a particularly ambiguous regulatory space. It is sometimes sold online as a 'research chemical' or 'peptide for research purposes only,' which is a common mechanism used to circumvent medicines regulations. The MHRA has issued broader warnings about the risks of purchasing unlicensed medicines and research chemicals online, noting that such products may be contaminated, mislabelled, or of unknown potency.^[13][14] Purchasing or importing such substances for personal use carries both health and legal risks.

The evidence base for BPC-157 in humans remains extremely limited. The majority of studies are conducted in rodent models, and while some findings are mechanistically interesting, animal data cannot be directly extrapolated to human safety or efficacy. NICE does not provide guidance on BPC-157, as it has not been evaluated through the standard health technology appraisal process. Similarly, retatrutide does not yet feature in NICE guidelines, though its drug class (incretin-based therapies) is well-represented in guidance for type 2 diabetes (NICE NG28) and obesity management (NICE CG189), as well as in relevant Technology Appraisals covering licensed agents such as semaglutide.

Potential Risks and Interactions to Be Aware Of

Combining BPC-157 and retatrutide introduces unpredictable gastrointestinal, cardiovascular, and metabolic risks, with no drug interaction studies available to guide safe use.

When considering the potential risks of using BPC-157 and retatrutide together, it is necessary to think about both the individual risk profiles of each substance and the unknown consequences of their interaction.

Risks associated with retatrutide (based on Phase 2 trial data and GLP-1 receptor agonist class effects):

• Significant gastrointestinal side effects, particularly at higher doses

• Increased heart rate, a recognised effect of GLP-1 receptor agonism

• Pancreatitis has been reported in association with GLP-1 receptor agonists as a class; a causal relationship has not been established, but individuals who develop severe, persistent abdominal pain with or without vomiting should stop use and seek urgent medical assessment^[11]

• Gallbladder disease, including gallstones, is a recognised class risk

• Delayed gastric emptying, which may reduce the absorption of oral medicines taken at the same time

• Possible thyroid C-cell effects, as observed with other GLP-1 receptor agonists in animal studies; clinical significance in humans is uncertain^[17]

Risks associated with BPC-157 (based on preclinical data and theoretical pharmacology):

• Unknown purity and sterility when sourced outside clinical settings

• Theoretical modulation of nitric oxide pathways, which could affect blood pressure; this is unproven in humans

• Possible interaction with growth factor signalling, raising theoretical concerns with long-term use; these remain speculative and are not established in human studies

• No established safe dosing range in humans

When used together, the overlapping effects on gastrointestinal motility, appetite, and potentially vascular tone could compound adverse effects in unpredictable ways. Individuals with pre-existing conditions — including cardiovascular disease, gastrointestinal disorders, gallbladder disease, diabetes, or a personal or family history of pancreatitis or thyroid cancer — face heightened risk. There are no known drug interaction studies examining BPC-157 alongside any approved or investigational pharmaceutical, making it impossible to predict how it might alter the absorption, distribution, metabolism, or excretion of retatrutide or vice versa.

Pregnancy, those trying to conceive, and breastfeeding individuals should avoid both substances entirely, given the complete absence of safety data in these groups.

What UK Guidelines Say About Unapproved Peptides

MHRA, NICE, and GMC guidance consistently restricts clinical use to licensed medicines; BPC-157 is prohibited under the WADA S0 category and falls entirely outside evidence-based UK practice.

UK regulatory and clinical guidance is clear on the use of unapproved substances. The MHRA advises the public to use only medicines that have been granted a UK marketing authorisation, as these have undergone rigorous assessment for quality, safety, and efficacy. Unlicensed products — including peptides sold online as research chemicals — have not been subject to this scrutiny and may pose serious health risks. The MHRA's guidance on buying medicines online highlights the particular dangers of purchasing such products from unregulated sources.

NICE guidelines on obesity management (NICE CG189: Obesity: identification, assessment and management; and related Technology Appraisals covering licensed agents such as semaglutide) and type 2 diabetes (NICE NG28) focus exclusively on licensed pharmacological interventions, lifestyle modification, and, where appropriate, bariatric surgery.^[12] There is no mention of peptide supplements or research chemicals within these frameworks, as such substances fall entirely outside evidence-based clinical practice.

The General Medical Council (GMC) guidance — Good Practice in Prescribing and Managing Medicines and Devices — acknowledges that clinicians may, in limited and justifiable circumstances, prescribe unlicensed or off-label medicines when no licensed alternative is suitable and when the prescriber takes individual clinical responsibility.^[15] However, this does not extend to substances such as BPC-157, for which there is no established evidence base, no regulatory approval, and no accepted clinical indication. No reputable UK clinician should be recommending BPC-157, either alone or in combination with any other substance, outside of a properly authorised clinical trial.

Athletes subject to anti-doping regulations should also be aware that BPC-157 is prohibited at all times under the World Anti-Doping Agency (WADA) Prohibited List, classified under S0 (Non-approved Substances) — a category covering any pharmacological substance not approved by a regulatory authority for human therapeutic use. Use of such compounds could result in sanctions, regardless of the health rationale offered.

Speaking to a Healthcare Professional Before Combining Substances

Consulting a GP or specialist before using any unapproved or experimental substance is essential to assess contraindications, explore licensed alternatives, and avoid serious unpredictable harm.

If you are considering using BPC-157, retatrutide, or any combination of unapproved or experimental substances, the most important first step is to speak openly with a qualified healthcare professional — ideally your GP or a specialist with relevant expertise in endocrinology, metabolic medicine, or sports and exercise medicine.

A healthcare professional can help you:

• Assess your individual health status and identify any contraindications or risk factors

• Explore licensed, evidence-based alternatives that may address your underlying health goals safely

• Review any existing medications for potential interactions, including the effect of delayed gastric emptying on oral medicines

• Refer you to appropriate specialist services, such as NHS weight management programmes or clinical trials, if relevant

It is understandable that individuals seeking solutions for weight management, metabolic health, or tissue recovery may feel frustrated by the pace of drug development and the limited availability of newer therapies. However, self-administering experimental compounds — particularly in combination — carries real and unpredictable risks that outweigh any theoretical benefit in the absence of clinical evidence. Both substances should be avoided in pregnancy, by those trying to conceive, and during breastfeeding, given the complete absence of safety data.

For those interested in accessing novel therapies through legitimate means, the NIHR's Be Part of Research portal (bepartofresearch.nihr.ac.uk) provides a searchable database of UK clinical trials, including studies in metabolic and weight management medicine. NHS weight management services offer evidence-based, supervised support for those with obesity-related health concerns.

When to seek urgent medical advice: If you have already used either of these substances and experience symptoms such as severe nausea or vomiting, chest pain, palpitations, signs of an allergic reaction (rash, swelling, difficulty breathing), or severe and persistent abdominal pain, you should contact your GP promptly or call NHS 111. In an emergency, dial 999.

Suspected side effects from any medicine or substance can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. The landscape of metabolic and regenerative medicine is evolving rapidly, and legitimate clinical trials offer a safe, monitored pathway for those interested in accessing novel therapies. Engaging with your healthcare team remains the safest and most effective route to achieving your health objectives.

Scientific References

1. European Medicines Agency (EMA) homepage.
2. Medicines and Healthcare products Regulatory Agency — GOV.UK.
3. Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2 Trial).
4. Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
5. Phase 2 Trial of Retatrutide for Obesity.
6. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes.
7. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes.
8. EMA Decision — Paediatric Investigation Plan for Retatrutide (P-0336-2024).
9. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Gallbladder and Biliary Diseases.
10. Association of GLP-1 Receptor Agonist Use With Gallbladder or Biliary Diseases.
11. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
12. Type 2 diabetes in adults: management (NG28).
13. MHRA urges public to avoid illegal online weight-loss medicines.
14. Medicines information — NHS.
15. Off-label or unlicensed use of medicines: prescribers' responsibilities.
16. GLP-1 receptor agonists in people with epilepsy: A scoping review of clinical data, safety, and therapeutic implications.
17. Thyroid Dysfunction Following Tirzepatide Use in a Post-thyroidectomy Patient on Stable Levothyroxine Therapy: A Case Study.

Frequently Asked Questions